Secreted frizzled-related protein 1

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference

Retrieved on: 
Friday, October 16, 2020

The data was generated as part of the Companys collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center.

Key Points: 
  • The data was generated as part of the Companys collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center.
  • The new data demonstrates IRS2-amplified colorectal cancer (CRC) cells upregulate -catenin expression, and treatment with NT219 significantly decreased the -catenin transcriptional activity in these cells.
  • -catenin signaling by Wnt has been shown to have a number of different cellular influences.
  • We expect top-line data from the first part of this important study in the second half of 2021.

Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration

Retrieved on: 
Monday, May 4, 2020

These abstracts were originally accepted for presentation during the 2020 DDW Conference which was to be held May 2-5 in Chicago, IL.

Key Points: 
  • These abstracts were originally accepted for presentation during the 2020 DDW Conference which was to be held May 2-5 in Chicago, IL.
  • Both abstracts describe pre-clinical results with a liver-targeted proprietary molecule that enhances Wnt signaling and stimulates tissue regeneration.
  • SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) are antibody-based molecules that enhance Wnt signaling.
  • Surrozen Wnt-mimetics, also referred to as SWAP (SurrozenWnt signalActivatingProteins), are bi-specific full-length human (IgG) antibodies that directly activate the canonical Wnt signaling pathway in target tissue.

Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology

Retrieved on: 
Monday, March 30, 2020

The article, Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements was published online today in Cell Chemical Biology .

Key Points: 
  • The article, Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements was published online today in Cell Chemical Biology .
  • The article describes Surrozens Wnt-mimetic platform comprising potent, multivalent antibodies directly activating the Wnt signaling pathway.
  • The article will appear in print in a future issue of Cell Chemical Biology.
  • Investors/Partners: Reza Afkhami VP, Corporate Development and Strategy Surrozen, Inc. [email protected] Media: Denise Powell Red House Consulting [email protected]

Surrozen to Present at Cowen and Company 40th Annual Health Care Conference

Retrieved on: 
Monday, March 2, 2020

The Wnt signaling pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes.

Key Points: 
  • The Wnt signaling pathway plays a critical role in stem cell maintenance, tissue regeneration and other important developmental processes.
  • Since its founding in 2016, Surrozen has developed two proprietary platforms to selectively modulate the Wnt pathway for the potential treatment of injury and disease.
  • Surrozen Wnt Signal Activators, also referred to as SWAPs (Surrozen Wnt Signal Activating Proteins), are bi-specific full-length human (IGg) antibodies that directly modulate the canonical Wnt signaling pathway in target tissue.
  • Surrozen Wnt Protein Enhancers, also referred to as SWEETS (Surrozen Wnt Signal Enhancer Engineered for Tissue Specificity), are uniquely engineered antibodies that mimic the activity of endogenous R-spondin.

Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors

Retrieved on: 
Wednesday, October 2, 2019

The article titled The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models was published in the peer-reviewed journal Cancer Letters.

Key Points: 
  • The article titled The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models was published in the peer-reviewed journal Cancer Letters.
  • Regulation of CLK2 and CLK3 is a novel strategy that leads to modulation of Wnt pathway signaling in cancer.
  • Our first-in-class CLK inhibitor, SM08502, had strong anti-tumor effects and diminished aberrant Wnt pathway activity in these mouse models and demonstrated its potential to treat gastrointestinal cancers.
  • SM08502s mechanism of action via inhibition of CDC-like kinases (CLKs) has potential to attenuate the expression of genes that control proliferation of tumor cells.

Wnt Signaling Pathway Inhibitor Pipeline Insight, 2019 Report Featuring Samumed, Mereo BioPharma, OncoMed Pharmaceuticals, & PRISM BioLab - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2019

The "Wnt Signaling Pathway Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wnt Signaling Pathway Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Wnt Signaling Pathway Inhibitor development.
  • Descriptive coverage of pipeline development activities for Wnt Signaling Pathway Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
  • The report assesses the active Wnt Signaling Pathway Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.